RESUMEN
AIM: To screen hepatitis B virus (HBV) genotypes and associated basal core promoter (BCP; T1762A/A1764) and precore (PC; A1896) mutations among the 100 HBV surface antigen (HBsAg) positive voluntary blood donors in France. METHODS: HBV genotypes were determined by using direct sequence analysis. Three methods were used to detect G1896A mutation: non-commercial real-time PCR (PCRTR°, line probe assay (InnoLiPA HBV PreCore, INNOGENETICS(®)) and direct sequencing of precore gene. HBV viral load was quantified with two commercial real-time PCR (COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HBV Test/Roche and Real Time HBV/M2000/Abbott). RESULTS: The mean age of donors was 30 (18-64). Patients were from Africa (42%), Europa (50%), and Asia (8%). HBV/D was the most predominant (37%) genotype followed by HBV/A (31%) and HBV/E (22%). PC and BCP mutants were found in 57% with Inno-LIPA HBV test and 59% with both PCRTR and sequencing methods. A significant difference in the viral load of blood donors with wild and PC mutants was observed with the Taqman Cobas real time PCR (3,19 Log(10) UI/ml versus 4,93 Log(10) UI/ml, p < 0.05). Precore phenotype determination was in agreement with the three PC mutation detection methods in 56% of cases. CONCLUSIONS: Non-Caucasian genotype E was present in the French blood donors. PC mutation was more common than BCP mutations in this study. As HBV infected blood donors were more often asymptomatic carriers, we could speculate that the G1896A mutation may favour the asymptomatic state, supporting previous observations.
Asunto(s)
Donantes de Sangre , Sistemas de Computación , Análisis Mutacional de ADN/métodos , Virus de la Hepatitis B/genética , Hepatitis B/virología , Técnicas para Inmunoenzimas , Mutación Puntual , Reacción en Cadena de la Polimerasa/métodos , Juego de Reactivos para Diagnóstico , Análisis de Secuencia de ADN , Viremia/virología , Adolescente , Adulto , África/etnología , Asia/etnología , Europa (Continente)/etnología , Femenino , Francia/epidemiología , Genotipo , Hepatitis B/epidemiología , Hepatitis B/genética , Antígenos de Superficie de la Hepatitis B/análisis , Virus de la Hepatitis B/clasificación , Virus de la Hepatitis B/aislamiento & purificación , Humanos , Masculino , Tamizaje Masivo , Persona de Mediana Edad , Viremia/epidemiología , Viremia/genética , Adulto JovenRESUMEN
UNLABELLED: Antitetanus antibodies titration is carried out by French National Blood Services (FNBSs) with the aim of seeking donors whose title of antibodies are greater or equal to 8 IU/ml. Different kits are used: ELISA antitetanus toxoid IgG (The Binding Site), ELISAT (Diagast), tetanus toxoid IgG ELISA (Diamed), ELISA IgG tetanus (Ingen). As the results obtained using these different reagents show some discrepancies with the control results carried out by the Laboratoire Français des Biotechnologies (LFB), it appeared necessary to harmonize the selection practices. With this intention a study of the different kits was initiated. METHOD: Different samples were used during this evaluation: (1) the Reference Control (RC) used by the FNBS; (2) a serum sample of high title; (3) a range of dilution of national standard. The following tests were carried out: (1) robustness with the evaluation of the contamination and the board effect; (2) linearity and repeatability (eight deposits of each standard, RC and points of national standard dilutions); (3) reproducibility; (4) homogeneity. After automatic dilution of the samples, the plates were then processed according to the protocol of the manufacturer. RESULTS: The study gives the CV in percentage of repeatability and reproducibility, the values of the standards provided as well as the bias compared to the RC and the uncertainty of measurements. CONCLUSION: This study gave the possibility to rank each kit compared to RC and to specify the variations which surround each result. This variation can explain the discrepancy of conformity of plasma when title is close to the threshold of selection.
Asunto(s)
Bancos de Sangre/normas , Donantes de Sangre , Juego de Reactivos para Diagnóstico/normas , Toxina Tetánica/inmunología , Francia , Humanos , Selección de Paciente , Valores de Referencia , Toxina Tetánica/aislamiento & purificaciónAsunto(s)
Donantes de Sangre , Hepacivirus/aislamiento & purificación , Anticuerpos contra la Hepatitis C/sangre , Hepatitis C/diagnóstico , Tamizaje Masivo/métodos , Técnicas de Amplificación de Ácido Nucleico , Viremia/diagnóstico , Transfusión Sanguínea , Hepatitis C/sangre , Hepatitis C/virología , Humanos , Estudios Retrospectivos , Sensibilidad y Especificidad , Carga Viral , Viremia/virologíaRESUMEN
BACKGROUND: The purpose of this study was to compare the performances of HCV core antigen (HCV Ag) testing with HCV RNA detection during the preseroconversion period. STUDY DESIGN AND METHODS: Six HCV antibody (HCV Ab)-negative and HCV RNA-positive blood samples from 6 donors and 135 serial samples from 28 patients who had undergone hemodialysis, collected a mean of 90 days before the detection of HCV Ab, were tested by ELISA for the detection of HCV Ag and by PCR to quantify HCV RNA. RESULTS: Five of the six donors were positive for HCV Ag. The donor with a negative HCV Ag test had the lowest viral load. In the hemodialysis patients, the 43 first specimens of the series were HCV RNA negative. Of the 92 specimens that were HCV RNA positive, 81 (88%) were positive for HCV Ag. Among the 74 samples with more than 10(5) RNA copies, 71 (96%) were HCV Ag positive. Average time from first viremic bleed to first HCV Ag-positive bleed was estimated at 2.0 days and that to first HCV Ab-positive bleed at 50.8 days. CONCLUSION: HCV Ag testing permits the detection of an HCV infection about 1.5 months earlier than the HCV Ab screening tests and an average of only 2 days later than quantitative HCV RNA detection in individual specimens.
Asunto(s)
Hepacivirus/inmunología , Hepatitis C/sangre , Anticuerpos Antivirales/sangre , Antígenos Virales/sangre , Hepacivirus/genética , Humanos , Métodos , ARN Viral/sangre , Factores de Tiempo , Carga ViralRESUMEN
OBJECTIVE: The aim of this study was to assess predictive factors for the progression to liver cirrhosis in hepatitis C. METHODS: One hundred thirty six patients (79 men; 57 women; mean age 39 years) with transfusion or intravenous drug use-associated hepatitis C virus (HCV) infection were studied. Sex, cause of infection, duration of contamination, and genotype were studied as predictive factors of progression to liver cirrhosis. RESULTS: One hundred twenty three patients presented with chronic hepatitis without cirrhosis and 13 had cirrhosis. At the time of liver biopsy, rates of cirrhosis were: 0% before 40 years, 10% between 40 and 60 years, and 47% after 60 years. (p < 0.05). Rates of cirrhosis according to the age at the time of contamination were as follows: 3% before 30 years; 16% between 30 and 50 years; 46% after 50 years even though duration of the disease was comparable in the three groups. In multivariate analysis, two independent factors were associated with liver cirrhosis: age at contamination and duration of infection. CONCLUSION: Duration of infection and especially age at contamination seem better correlated with the probability of cirrhosis than the route of transmission or the genotype 1b. The results of this study suggest that progression to cirrhosis is slower in cases of contamination before 30 years of age than later on. Age at the time of contamination is an important predictive factor of progression to cirrhosis.
Asunto(s)
Hepatitis C/complicaciones , Cirrosis Hepática/etiología , Adolescente , Adulto , Factores de Edad , Anciano , Femenino , Hepacivirus , Hepatitis C/virología , Humanos , Cirrosis Hepática/virología , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: To verify the criteria for human T-lymphotropic virus (HTLV) seropositivity in Western blot (WB) proposed by the Retrovirus Study Group of the French Society of Blood Transfusion, 186 blood donations that were repeatedly reactive in HTLV enzyme-linked immunosorbent assay, selected according to their WB pattern, were tested by polymerase chain reaction (PCR) and radioimmunoprecipitation assay (RIPA). STUDY DESIGN AND METHODS: In two commercially available WBs, 12 samples were confirmed as positive (rgp21+p19+p24) and 174 were interpreted as indeterminate (one or two reactivities to these proteins). The primer pairs used for the PCR allowed the amplification of type I (HTLV-I) or type II (HTLV-II) (or both) sequences. The RIPA was performed with two 35S-labeled cell lines: HTLV-I infected HUT 102/B2 and HTLV-II-infected MoT. RESULTS: Of the 12 positive samples, 11 were classified as HTLV-I-positive and one as HTLV-II-positive. Among the 174 indeterminate samples, three (WB pattern: rgp21+, p19+, p24-) were HTLV-I positive in PCR (one of them was positive in RIPA also); the other 171 were HTLV negative. CONCLUSION: In the study of a population in which 97 percent of HTLV infections are due to HTLV-I, these data support the three-protein criteria (rgp21, p19, and p24) for a positive blot reading. No HTLV infection was observed when rgp21 did not react. Consequently, p19 and/or p24 band patterns represent false reactivity and do not require PCR or RIPA confirmation. To discriminate between false- and true-positive results in the absence of MTA-1 or K55 reactivity, PCR and/or RIPA is required only when rgp21 reactivity is associated with one gag band (p19 or p24).
Asunto(s)
Donantes de Sangre , Infecciones por HTLV-I/diagnóstico , Virus Linfotrópico T Tipo 1 Humano/aislamiento & purificación , Secuencia de Bases , Francia , Humanos , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa/métodos , Radioinmunoensayo/métodosRESUMEN
The sensitivity of the most recent generation of anti-hepatitis C virus (anti-HCV) screening tests from seven manufacturers was evaluated with a common panel of 530 specimens from 320 HCV-infected subjects. This panel included 221 samples from 57 seroconverters (53 pre-sero conversion negative specimens and 168 positive samples) and 309 selected specimens from 263 other HCV-infected patients of which 19% exhibited NS3 or core reactivity alone with the presence of HCV-RNA assessed by PCR. None of the seven screening tests detected all infectious and antibody-positive specimens. However, important differences were observed between these assays in the number of false-negative results, which seemed mainly due to nonreactivity of antibody to the NS3 antigen.
Asunto(s)
Hepacivirus/aislamiento & purificación , Anticuerpos contra la Hepatitis C/sangre , Hepatitis C/inmunología , Tamizaje Masivo/métodos , Reacciones Antígeno-Anticuerpo , Estudios de Evaluación como Asunto , Francia , Hepacivirus/inmunología , Humanos , Laboratorios , Valor Predictivo de las Pruebas , Sensibilidad y EspecificidadRESUMEN
The transfusion-related risk of transmission of hepatitis C virus (HCV) was evaluated in France for the periods before and after exclusion of donor blood units with the surrogate markers elevated alanine aminotransferase (ALT) levels and antibody to hepatitis B core antigen (anti-HBc). A total of 1,412 blood recipients undergoing surgery were followed up prospectively in the period from 1986 to 1989. The stored serum samples were tested for antibodies to HCV by an enzyme immunoassay (EIA) and the result in reactive sera confirmed by a recombinant immunoblot assay (RIBA). The risk of HCV transmission was estimated by the maximum likelihood method for a subpopulation of 892 recipients divided into three groups. Of 55 (3.9%) EIA positive patients, 56.4% were found to be positive prior to transfusion. HCV seroconversion (positive RIBA) occurred in 22 patients (1.6%). The risk of HCV transmission per 1,000 transfused blood units decreased significantly from 4.11 in Group 1 (receiving non-screened blood) to 3.43 in Group II (receiving ALT screened blood) and to 1.40 in Group III (receiving ALT and anti-HBc screened blood). These results demonstrate that screening of donors for surrogate markers had reduced the risk of HCV transmission before the introduction of a systematic anti-HCV screening policy in France in March 1990.
Asunto(s)
Alanina Transaminasa/sangre , Donantes de Sangre , Transfusión Sanguínea , Anticuerpos contra la Hepatitis B/sangre , Antígenos del Núcleo de la Hepatitis B/inmunología , Hepatitis C/transmisión , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Humanos , Immunoblotting , Lactante , Funciones de Verosimilitud , Masculino , Persona de Mediana Edad , Estudios ProspectivosRESUMEN
OBJECTIVE: To evaluate the serological and epidemiological characteristics of HTLV-I/II-positive blood donors in continental France during the first 6 months of universal screening of blood donations (n = 1,816,927). METHOD: A collaborative investigation of all confirmed anti-HTLV-I/II-positive samples reported by blood transfusion centres was performed. Seventy-three out of 77 reported samples were retested at two reference laboratories. Epidemiological data on risk factors were compiled. RESULTS: Of the 73 retested samples, 66 were confirmed to be HTLV-I-positive and one to be HTLV-II-positive; six samples were designated false-positive, mainly because of non-specific reactivity to recombinant gp21 in Western blot. The overall prevalence of HTLV-I/II in continental France is 0.039 per thousand. The main risk factor identified for HTLV-I infection was directly (origin) or indirectly (heterosexual contact) linked to endemicity in the Caribbean. The cost per case of avoided contamination in the 6-month period of this study was 1.36 million French francs. CONCLUSIONS: Sixty-two per cent of HTLV-I/II-infected blood donations would not have been discarded through the previous targeted HTLV screening or through other mandatory tests, including anti-hepatitis B core. To avoid false-positive results, we propose a new algorithm of diagnosis.
Asunto(s)
Donantes de Sangre , Anticuerpos Antideltaretrovirus/sangre , Infecciones por HTLV-I/epidemiología , Infecciones por HTLV-II/epidemiología , Tamizaje Masivo , Adulto , Western Blotting , ADN Viral/sangre , Ensayo de Inmunoadsorción Enzimática , Reacciones Falso Positivas , Femenino , Francia/epidemiología , Infecciones por HTLV-I/sangre , Infecciones por HTLV-I/prevención & control , Infecciones por HTLV-II/sangre , Infecciones por HTLV-II/prevención & control , Virus Linfotrópico T Tipo 1 Humano/inmunología , Virus Linfotrópico T Tipo 1 Humano/aislamiento & purificación , Virus Linfotrópico T Tipo 2 Humano/inmunología , Virus Linfotrópico T Tipo 2 Humano/aislamiento & purificación , Humanos , Masculino , Tamizaje Masivo/economía , Reacción en Cadena de la Polimerasa , Prevalencia , Provirus/aislamiento & purificación , Ensayo de Radioinmunoprecipitación , Factores de Riesgo , Encuestas y Cuestionarios , Viremia/microbiología , Indias Occidentales/etnologíaRESUMEN
HIV seroprevalence decreased from 0.62% in 1985 to 0.11% in the first 1990 semester. However, the number of regular blood donors screened as seropositive remains constant since 1988: 48 in 1988, 49 in 1989 and 25 in the first 6 months of 1990. From these data, from reports on recipients and due to the exclusion of 30% of such donors by anti-HBc screening, the residual risk to transmit HIV by blood transfusion was estimated to 17 blood donations per year in France. No significant change was observed throughout these years either in sex ratio or in the repartition into age groups. The number of HIV-infected subjects through the heterosexual route has not increased. The number of homosexuals and of IVDA has dramatically decreased since 1985, homosexuals still representing the major at-risk group.
Asunto(s)
Donantes de Sangre , Seroprevalencia de VIH , Adulto , Factores de Edad , Transfusión Sanguínea , Femenino , Francia/epidemiología , Anticuerpos contra la Hepatitis B/análisis , Antígenos del Núcleo de la Hepatitis B/inmunología , Homosexualidad , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Factores Sexuales , Conducta Sexual , Abuso de Sustancias por Vía IntravenosaAsunto(s)
Alanina Transaminasa/sangre , Hepatitis C/prevención & control , Reacción a la Transfusión , Biomarcadores , Donantes de Sangre , Transfusión Sanguínea/normas , Estudios de Cohortes , Estudios Transversales , Francia/epidemiología , Hepacivirus/inmunología , Anticuerpos Antihepatitis/análisis , Anticuerpos Antihepatitis/biosíntesis , Hepatitis C/diagnóstico , Hepatitis C/epidemiología , Hepatitis C/transmisión , Humanos , Factores de RiesgoRESUMEN
During a 3 year period, from August 1985 to August 1988, 18 HIV 2-infected blood donors were detected in France as a result of systematic HIV 1 screening. These sera were characterized as HIV 2 by specific Western blot and synthetic peptides. Within the same period, 40 other HIV 2 infected subjects were identified by our study group, independently of blood donations. Thirty of these 58 subjects living in France originate from West Africa (8 blood donors), 3 (I blood donor) are Portuguese men who had lived in West Africa and 25 (9 blood donors) are of French origin; among these, 16 have had a known close contact with West Africa. When HIV 2-infected subjects were asymptomatic, cross reactivity between antibodies to HIV 2 and HIV 1 proteins was generally observed with the two-step ELISA assays using total HIV 1 proteins; it was poor with the competitive assays and variable with the assays using recombinant proteins. When the subjects had signs of immunodeficiency, cross reactivity decreased. The data confirm that HIV 2 is not widespread in France and that most of HIV 2-infected but asymptomatic subjects are recognized by several HIV 1 ELISA assays. Accordingly, systematic screening for HIV 2 with an additional test cannot be recommended at the present time, but a combined HIV 1 and HIV 2 test will be useful when available.